Arcus Biosciences, Inc.
RCUS
$24.90
$0.040.16%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.29% | -12.77% | -46.74% | 100.00% | -2,700.00% |
| Total Depreciation and Amortization | -33.33% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.71% | -7.14% | 0.00% | -18.75% | -61.11% |
| Change in Net Operating Assets | 16.22% | -30.43% | -79.21% | -678.95% | 0.00% |
| Cash from Operations | -4.55% | -20.00% | -473.08% | -41.49% | -6,500.00% |
| Capital Expenditure | -- | 0.00% | 100.00% | -- | 75.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 245.45% | -448.08% | 382.14% | 117.46% | 120.00% |
| Cash from Investing | 256.25% | -456.86% | 372.41% | 117.46% | 118.93% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.89% | 9,433.33% | 300.00% | 0.00% | -37.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.89% | 14,400.00% | -83.33% | 2,500.00% | -37.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.00% | 68.63% | -122.22% | 293.10% | -27.59% |